{"id":49999,"date":"2022-10-24T19:02:11","date_gmt":"2022-10-24T17:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-biopharmaceutical-contract-manufacturing-market-trends-and-forecasts-2022-2035-capability-and-expertise-expansions-by-cmos-to-become-one-stop-shops-researchandmarkets-com\/"},"modified":"2022-10-24T19:02:11","modified_gmt":"2022-10-24T17:02:11","slug":"global-biopharmaceutical-contract-manufacturing-market-trends-and-forecasts-2022-2035-capability-and-expertise-expansions-by-cmos-to-become-one-stop-shops-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-biopharmaceutical-contract-manufacturing-market-trends-and-forecasts-2022-2035-capability-and-expertise-expansions-by-cmos-to-become-one-stop-shops-researchandmarkets-com\/","title":{"rendered":"Global Biopharmaceutical Contract Manufacturing Market Trends and Forecasts, 2022-2035 – Capability and Expertise Expansions by CMOs to become One-Stop-Shops – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Biopharmaceutical Contract Manufacturing Market by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022 – 2035”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe “Biopharmaceutical Contract Manufacturing Market” report features an extensive study of the current market landscape and the likely future potential associated with the biopharmaceutical contract manufacturing market, over the next decade.\n<\/p>\n

\nOver the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs.\n<\/p>\n

\nFurther, with the advent of novel technologies, biologics have made a significant impact in the pharmaceutical domain, delivering ground-breaking treatment for a myriad of disease indications, including immunological, oncological and rare disorders. In this context, it is worth highlighting those 14 biopharmaceutical products (including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins) were approved in the US alone, in 2021.\n<\/p>\n

\nFurther, promising results from ongoing clinical research initiatives have encouraged various government and private firms to make significant investments in this domain. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges.\n<\/p>\n

\nSome of the key concerns of contemporary innovators include rate of attrition of pipeline drugs \/ therapies, prolonged development timelines, current facility limitations, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Therefore, therapy developers are actively exploring avenues that enable them to overcome the existing challenges. Amongst other alternatives, outsourcing has emerged as a lucrative option for biologic drug developers.\n<\/p>\n

\nCurrently, a significant number of players engaged in the biopharmaceutical domain prefer to outsource various operations to contract service providers (such as biologics manufacturing). In fact, currently over 275 companies claim to be biopharma CDMO \/ biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics.\n<\/p>\n

\nFor this purpose, substantial expansions, and mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs of their clientele. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical contract manufacturing market (biopharma CDMO \/ biopharma CMO) to grow at a commendable pace in the coming years.\n<\/p>\n

\nScope of the Report<\/strong>\n<\/p>\n

\nOne of the key objectives of the report was to estimate the existing market size and estimate the future size of biopharmaceutical contract manufacturing market. We have provided informed estimates on the evolution of the market, over the period 2022-2035.\n<\/p>\n

\nIn order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.\n<\/p>\n

\nOur year-wise projections of the current and future opportunity have further been segmented on the basis of<\/strong>\n<\/p>\n